Downregulation of ST6GAL1 Promotes Liver Inflammation and Predicts Adverse Prognosis in Hepatocellular Carcinoma

References

• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Pinto Marques H, Gomes da Silva S, De Martin E, Agopian VG, Martins PN. Emerging biomarkers in HCC patients: current status. Int J Surg. 2020;82S:70–76. doi:10.1016/j.ijsu.2020.04.043
   PubMed Web of Science ®Google Scholar
• Ruf B, Heinrich B, Greten TF. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cell Mol Immunol. 2021;18(1):112–127. doi:10.1038/s41423-020-00572-w
   PubMed Web of Science ®Google Scholar
• Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222–232. doi:10.1038/s41590-018-0044-z
   PubMed Web of Science ®Google Scholar
• Lei X, Lei Y, Li J-K, et al. Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126–133. doi:10.1016/j.canlet.2019.11.009
   PubMed Web of Science ®Google Scholar
• Lurje I, Hammerich L, Tacke F. Dendritic cell and T cell crosstalk in liver fibrogenesis and hepatocarcinogenesis: implications for prevention and therapy of liver cancer. Int J Mol Sci. 2020;21(19):7378. doi:10.3390/ijms21197378
   PubMed Web of Science ®Google Scholar
• Kurebayashi Y, Ojima H, Tsujikawa H, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018;68(3):1025–1041. doi:10.1002/hep.29904
   PubMed Web of Science ®Google Scholar
• Fu C, Jiang A. Dendritic cells and CD8 T cell immunity in tumor microenvironment. Front Immunol. 2018;9:3059. doi:10.3389/fimmu.2018.03059
   PubMed Web of Science ®Google Scholar
• Hedlund M, Ng E, Varki A, Varki NM. alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res. 2008;68(2):388–394. doi:10.1158/0008-5472.CAN-07-1340
   PubMed Web of Science ®Google Scholar
• Han Y, Liu Y, Fu X, et al. miR-9 inhibits the metastatic ability of hepatocellular carcinoma via targeting beta galactoside alpha-2,6-sialyltransferase 1. J Physiol Biochem. 2018;74(3):491–501. doi:10.1007/s13105-018-0642-0
   PubMed Web of Science ®Google Scholar
• Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540–555. doi:10.1038/nrc3982
   PubMed Web of Science ®Google Scholar
• Chen X, Wang L, Yu X, Wang S, Zhang J. Caveolin-1 facilitates cell migration by upregulating nuclear receptor 4A2/retinoid X receptor α-mediated β-galactoside α2,6-sialyltransferase I expression in human hepatocarcinoma cells. Int J Biochem Cell Biol. 2021;137:106027. doi:10.1016/j.biocel.2021.106027
   PubMed Web of Science ®Google Scholar
• Garnham R, Scott E, Livermore KE, Munkley J. ST6GAL1: a key player in cancer. Oncol Lett. 2019;18(2):983–989. doi:10.3892/ol.2019.10458
   PubMed Web of Science ®Google Scholar
• Dorsett KA, Marciel MP, Hwang J, Ankenbauer KE, Bhalerao N, Bellis SL. Regulation of ST6GAL1 sialyltransferase expression in cancer cells. Glycobiology. 2021;31(5):530–539. doi:10.1093/glycob/cwaa110
   PubMed Web of Science ®Google Scholar
• Morosi LG, Cutine AM, Cagnoni AJ, et al. Control of intestinal inflammation by glycosylation-dependent lectin-driven immunoregulatory circuits. Sci Adv. 2021;7(25). doi:10.1126/sciadv.abf8630
   PubMed Web of Science ®Google Scholar
• Liu Y, Yu H, Wu S, et al. Plasma ST6GAL1 regulates IgG sialylation to control IgA nephropathy progression. Ther Adv Chronic Dis. 2021;12:20406223211048644. doi:10.1177/20406223211048644
   Web of Science ®Google Scholar
• Punch PR, Irons EE, Manhardt CT, Marathe H, Lau JTY. The sialyltransferase ST6GAL1 protects against radiation-induced gastrointestinal damage. Glycobiology. 2020;30(7):446–453. doi:10.1093/glycob/cwz108
   PubMed Web of Science ®Google Scholar
• Nasirikenari M, Segal BH, Ostberg JR, Urbasic A, Lau JT. Altered granulopoietic profile and exaggerated acute neutrophilic inflammation in mice with targeted deficiency in the sialyltransferase ST6Gal I. Blood. 2006;108(10):3397–3405. doi:10.1182/blood-2006-04-014779
   PubMed Web of Science ®Google Scholar
• Wang Y, Khan A, Antonopoulos A, et al. Loss of α2-6 sialylation promotes the transformation of synovial fibroblasts into a pro-inflammatory phenotype in arthritis. Nat Commun. 2021;12(1):2343. doi:10.1038/s41467-021-22365-z
   PubMed Web of Science ®Google Scholar
• Myojin Y, Kodama T, Maesaka K, et al. ST6GAL1 is a novel serum biomarker for Lenvatinib-susceptible FGF19-driven hepatocellular carcinoma. Clin Cancer Res. 2021;27(4):1150–1161. doi:10.1158/1078-0432.CCR-20-3382
   PubMed Web of Science ®Google Scholar
• Holdbrooks AT, Ankenbauer KE, Hwang J, Bellis SL. Regulation of inflammatory signaling by the ST6Gal-I sialyltransferase. PLoS One. 2020;15(11):e0241850. doi:10.1371/journal.pone.0241850
   PubMed Web of Science ®Google Scholar
• Zhou W, Ma Y, Zhang J, et al. Predictive model for inflammation grades of chronic hepatitis B: large-scale analysis of clinical parameters and gene expressions. Liver Int. 2017;37(11):1632–1641. doi:10.1111/liv.13427
   PubMed Web of Science ®Google Scholar
• Wang M, Gong Q, Zhang J, et al. Characterization of gene expression profiles in HBV-related liver fibrosis patients and identification of ITGBL1 as a key regulator of fibrogenesis. Sci Rep. 2017;7:43446. doi:10.1038/srep43446
   PubMed Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. Liver enzymes, metabolomics and genome-wide association studies: from systems biology to the personalized medicine. World J Gastroenterol. 2015;21(3):711–725. doi:10.3748/wjg.v21.i3.711
   PubMed Web of Science ®Google Scholar
• Yuan SX, Wang J, Yang F, et al. Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. Hepatology. 2016;63(2):499–511. doi:10.1002/hep.27893
   PubMed Web of Science ®Google Scholar
• Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival. J Hepatol. 2019;70(6):1262–1277. doi:10.1016/j.jhep.2019.01.028
   PubMed Web of Science ®Google Scholar
• Li X, Li C, Zhang L, et al. The significance of exosomes in the development and treatment of hepatocellular carcinoma. Mol Cancer. 2020;19(1):1. doi:10.1186/s12943-019-1085-0
   PubMed Web of Science ®Google Scholar
• Li F, Ding J. Sialylation is involved in cell fate decision during development, reprogramming and cancer progression. Protein Cell. 2019;10(8):550–565. doi:10.1007/s13238-018-0597-5
   PubMed Web of Science ®Google Scholar
• Holdbrooks AT, Britain CM, Bellis SL. ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor. J Biol Chem. 2018;293(5):1610–1622. doi:10.1074/jbc.M117.801480
   PubMed Web of Science ®Google Scholar
• Souady J, Hülsewig M, Distler U, et al. Differences in CD75s- and iso-CD75s-ganglioside content and altered mRNA expression of sialyltransferases ST6GAL1 and ST3GAL6 in human hepatocellular carcinomas and nontumoral liver tissues. Glycobiology. 2011;21(5):584–594. doi:10.1093/glycob/cwq200
   PubMed Web of Science ®Google Scholar
• Poon TCW, Chiu CHS, Lai PBS, et al. Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma. World J Gastroenterol. 2005;11(42):6701–6706. doi:10.3748/wjg.v11.i42.6701
   PubMed Web of Science ®Google Scholar
• Cao Y, Merling A, Crocker PR, Keller R, Schwartz-Albiez R. Differential expression of beta-galactoside alpha2,6 sialyltransferase and sialoglycans in normal and cirrhotic liver and hepatocellular carcinoma. Lab Invest. 2002;82(11):1515–1524. doi:10.1097/01.LAB.0000038503.34655.98
   PubMed Web of Science ®Google Scholar
• Kroes RA, Moskal JR. The role of DNA methylation in ST6Gal1 expression in gliomas. Glycobiology. 2016;26(12):1271–1283. doi:10.1093/glycob/cww058
   PubMed Web of Science ®Google Scholar
• Antony P, Rose M, Heidenreich A, Knüchel R, Gaisa NT, Dahl E. Epigenetic inactivation of ST6GAL1 in human bladder cancer. BMC Cancer. 2014;14:901. doi:10.1186/1471-2407-14-901
   PubMed Web of Science ®Google Scholar
• Oswald DM, Zhou JY, Jones MB, Cobb BA. Disruption of hepatocyte Sialylation drives a T cell-dependent pro-inflammatory immune tone. Glycoconj J. 2020;37(3):395–407. doi:10.1007/s10719-020-09918-y
   PubMed Web of Science ®Google Scholar
• Danilo M, Chennupati V, Silva JG, Siegert S, Held W. Suppression of Tcf1 by Inflammatory cytokines facilitates effector CD8 T cell differentiation. Cell Rep. 2018;22(8):2107–2117. doi:10.1016/j.celrep.2018.01.072
   PubMed Web of Science ®Google Scholar
• Liu P, Chen L, Zhang H. Natural killer cells in liver disease and hepatocellular carcinoma and the NK cell-based immunotherapy. J Immunol Res. 2018;2018:1206737. doi:10.1155/2018/1206737
   PubMed Web of Science ®Google Scholar
• Vivian J, Rao AA, Nothaft FA, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35(4):314–316. doi:10.1038/nbt.3772
   PubMed Web of Science ®Google Scholar
• Menyhárt O, Á N, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci. 2018;5(12):181006. doi:10.1098/rsos.181006
   PubMed Web of Science ®Google Scholar
• Koch A, De Meyer T, Jeschke J, Van Criekinge W. MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data. BMC Genomics. 2015;16:636. doi:10.1186/s12864-015-1847-z
   PubMed Web of Science ®Google Scholar
• Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2018;10(3):277–288. doi:10.2217/epi-2017-0118
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. doi:10.1093/nar/28.1.27
   PubMed Web of Science ®Google Scholar
• Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947–1951. doi:10.1002/pro.3715
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–D551. doi:10.1093/nar/gkaa970
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–4202. doi:10.1093/bioinformatics/btz210
   PubMed Web of Science ®Google Scholar